← All trials
NCT06072131
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 4, 2023
- Primary completion
- Jul 31, 2030
- Completion date
- Nov 30, 2030
- First posted
- Oct 10, 2023
- Last posted
- Nov 7, 2023
- Enrollment
- 504
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Acrotech Biopharma LLCLead sponsor
- Acrotech Biopharma LLCStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.